Reach Us +1-947-333-4405


BRAFV600E Is A Negative Prognosticator In Pediatric Ganglioglioma | 16409
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 1147

Journal of Clinical & Experimental Pathology received 1147 citations as per google scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

BRAFV600E is a negative prognosticator in pediatric ganglioglioma

3rd International Conference and Exhibition on Pathology

Sonika Dahiya

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.012

Gangliogliomas are typically low-grade neuroepithelial tumors seen in the pediatric and young adult populations. Despite their often bland histologic appearance, these tumors can recur with varying frequency; however, little data exist that adequately predict ganglioglioma recurrence in children. To identify potential histopathologic features predictive of recurrence- free survival, a series of 53 pediatric gangliogliomas were evaluated. Fifteen patients (28%) exhibited disease recurrence during the study period. BRAF V600E immunohistochemistry was performed on 47 tumor samples, and histopathologic findings were analyzed against survival data. Histopathologic features associated with longer recurrence- free survival included oligodendroglial morphology, tumor cell density, microvascular proliferation, and the presence of a lymphoplasmacytic inflammatory infiltrate. Eighteen tumors (38.3%) exhibited positive BRAF V600E staining. Positive BRAF V600E staining was associated with shorter recurrence- free survival. The present study marks the largest pediatric cohort of World Health Organization (WHO) grade I gangliogliomas with accompanying histopathologic and survival data. Collectively, the combined use of histopathologic and molecular features to stratify grade I gangliogliomas into low and high risk groups provides important information relevant to the management of children and young adults with these rare tumors.
Sonika Dahiya completed her medical schooling and Pathology residency in India followed by a research fellowship in Molecular Pathology (Massachusetts General Hospital and Harvard Medical School), retraining in Pathology (New York University School of Medicine) and Neuropathology fellowship (Washington University School of Medicine) in USA. She is currently an Assistant Professor in Department of Pathology & Immunology at Washington University School of Medicine in St. Louis. Her research interest is investigation of prognostic and predictive markers in brain tumors.